UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 25, 2016
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-31812 | 58-2301143 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
210 Main Street West Baudette, Minnesota | 56623 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (218) 634-3500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On May 25, 2016, ANI Pharmaceuticals, Inc. (the "Company") held its 2016 Annual Meeting of Stockholders. The following matters, all of which were set forth in the Company's proxy statement for the 2016 Annual Meeting, were voted on and approved by the Company's stockholders. The voting results for each proposal are set forth below.
| 1. | Election of the nominees listed below to serve on the Board of Directors of the Company for a term of one year. |
| Nominee | For | Withheld | Broker Non-Votes | |||
| 1. Robert E. Brown, Jr. | 6,831,152 | 162,167 | 2,523,509 | |||
| 2. Arthur S. Przybyl | 6,936,085 | 57,234 | 2,523,509 | |||
| 3. Fred Holubow | 6,954,895 | 38,424 | 2,523,509 | |||
| 4. Peter A. Lankau | 6,956,601 | 36,718 | 2,523,509 | |||
| 5. Tracy L. Marshbanks, Ph.D. | 6,928,741 | 64,578 | 2,523,509 | |||
| 6. Thomas A. Penn | 6,828,889 | 164,430 | 2,523,509 | |||
| 7. Daniel Raynor | 6,578,605 | 414,714 | 2,523,509 |
| 2. | Approval of the Company's 2016 Employee Stock Purchase Plan. |
| For | Against | Abstain | Broker Non-Votes | |||
| 6,927,867 | 48,193 | 17,259 | 2,523,509 | |||
| 3. | Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2016. |
| For | Against | Abstain | Broker Non-Votes | |||
| 9,474,808 | 24,970 | 17,050 | 0 | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANI PHARMACEUTICALS, INC. | ||
| By: | /s/ Stephen P. Carey | |
| Stephen P. Carey | ||
| Vice President and Chief Financial Officer | ||
| Dated: May 26, 2016 | ||